Hepatitis C virus (HCV) infection is a common risk factor for the development of liver cancer. The molecular mechanisms underlying this effect are only partially understood. Here, we show that the HCV protein, nonstructural protein (NS) 5B, directly binds to the tumor suppressor, NORE1A (RASSF5), and promotes its proteosomal degradation. In addition, we show that NORE1A colocalizes to sites of HCV viral replication and suppresses the replication process. Thus, NORE1A has antiviral activity, which is specifically antagonized by NS5B. Moreover, the suppression of NORE1A protein levels correlated almost perfectly with elevation of Ras activity in primary human samples. Therefore, NORE1A inactivation by NS5B may be essential for maximal HCV replication and may make a major contribution to HCVinduced liver cancer by shifting Ras signaling away from prosenescent/proapoptotic signaling pathways. Conclusion: HCV uses NS5B to specifically suppress NORE1A, facilitating viral replication and elevated Ras signaling. (HEPATOLOGY 2017;65:1462-1477. D espite recent advances in treatment, the blood-borne pathogen hepatitis C virus (HCV) remains a serious public health concern, with over 170 million cases worldwide. (1, 2) Chronic HCV infection increases the risk of developing liver cirrhosis and hepatocellular carcinoma (HCC), (3) the third-leading cause of cancer-related deaths.
D espite recent advances in treatment, the blood-borne pathogen hepatitis C virus (HCV) remains a serious public health concern, with over 170 million cases worldwide. (1, 2) Chronic HCV infection increases the risk of developing liver cirrhosis and hepatocellular carcinoma (HCC), (3) the third-leading cause of cancer-related deaths. (4) In Western countries, the increasing numbers of HCV infections is primarily responsible for the increased incidence of HCC. (5) HCV is a member of the Flaviviridae family. Similar to other flaviviruses, replication of the plus-stranded RNA genome occurs exclusively in the cytoplasm of host cells. The 9.6-kilobase RNA is translated as a single polyprotein of approximately 3,000 amino acids. (6) The viral polyprotein is subsequently cleaved by a Abbreviations: ALLN, N-Acetyl-Leu-Leu-Nle-CHO; BrU, 5-bromouridine; cDNA, complementary DNA; Cy, cyanine; DAPI, 4 0 ,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; E6AP, E6-associated protein; FITC, fluorescein isothiocyanate; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein; GST, glutathione S-transferase; HA, hemagglutinin; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HMW, higher-molecular-weight; IB, immunoblotting; IgG, immunoglobulin G; IP, immunoprecipitation; LTPDS, Liver Tissue Procurement and Distribution System; NIH, National Institutes of Health; NS, nonstructural protein; NTR, nontranslated region; PBS, phosphate-buffered saline; PK, proteinase K; Rb, retinoblastoma; RCs, replication complexes; RdRp, RNA-dependent RNA polymerase; SDS-PAGE, sodium dodecyl sulfate polyacrylamide electrophoresis; shRNA, short hairpin RNA.
combination of host and viral proteases into four structural (core, E1, E2, and p7) and six nonstructural (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) proteins. (6) The mechanism whereby the cytoplasmically replicating HCV induces deregulation of the hepatocyte cell cycle leading to carcinogenesis is not well understood. Although HCV infection induces inflammation, an event thought to contribute to the development of HCC, there are emerging lines of evidence that HCV proteins, either alone or in combination, contribute to carcinogenesis. For example, transgenic mice that express the HCV polyprotein develop HCC at higher incidence. (7) Interestingly, these mice do not develop hepatic inflammation, which supports the involvement of HCV proteins in the development of HCC. (7) Additionally, expression of the HCV core, NS3, and NS5A alter cellular proliferation and may contribute to hepatocarcinogenesis. (8) (9) (10) (11) (12) (13) Recently, the viral RNA-dependent RNA polymerase (RdRp), NS5B, has also been implicated as an oncoprotein. Indeed, NS5B binds and induces the degradation of the tumor suppressor, retinoblastoma (Rb), protein through recruitment of the E3 ubiquitin ligase, E6-associated protein (E6AP). (14) The goal of this study was to identify and investigate the role of additional host cell proteins that modulate HCV replication and pathogenesis. Using a BacterioMatch two-hybrid approach, we identified NORE1A, a Ras effector/tumor suppressor that mediates the prosenescence and proapoptotic effects of the Ras oncoprotein as a potential binding partner of NS5B. Here, we confirm that the interaction is physiological and demonstrate that NORE1A can suppress HCV viral replication. In addition, we show that NS5B acts to promote the proteosomal degradation of NORE1A.
These observations are likely to be physiologically relevant given that we also show that loss of expression of NORE1A protein in primary HCC correlates well with HCV infection. Thus, we present evidence for antiviral effects of RASSF family tumor suppressors and identify a novel mechanism by which NS5B can promote cancer during HCV infection by suppressing NORE1A.
Materials and Methods

PLASMIDS
Green fluorescent protein (GFP)-NORE1A and GFP-NORE1B plasmids have been described. (15) GFP-BRaf was obtained from Addgene, Cambridge, MA. Hemagglutinin (HA)-ubiquitin plasmid was a kind gift from Dr. Chee Gun-Lee. pNTAP vector was purchased from Stratagene. The plasmids, pNTAP-NS5B and pFLAG-CMV2-NS5B, were generated by amplifying the NS5B coding sequence (1-591 amino acids). The plasmid, pNTAP-NS5BCD21, containing full-length NS5B truncated by 21 amino acids at the C terminus, was also generated by PCR.
CELL CULTURE
Huh-7 (human hepatocellular carcinoma) and Hek293 (human embryonic kidney) cells were cultured in Dulbecco's modified Eagle's medium (SigmaAldrich, St. Louis, MO) supplemented with 10% fetal bovine serum, L-glutamine (500 lM; Invitrogen Carlsbad CA), and penicillin/streptomycin (liquid, 1,0003; Invitrogen). NS5B stable 293 (termed as 2.3) cells were generated by transfection of the plasmid encoding
ARTICLE INFORMATION:
Flag-NS5BCD21. HCV subgenomic replicon cells (MH-14; kind gift of Dr. Kunitada Shimotohno) and a full-length HCV genomic cell line (C-5B; obtained from Dr. Stanley Lemon) were cultured in the abovedescribed medium supplemented with 500 lg/lL of G418 (Invitrogen). Plasmid transfection was performed by LipoD293 reagent (Signa Gen Laboratories, Rockville, MD) in accord with the manufacturer's protocol.
ANTIBODIES
Anti-NS5B (rabbit polyclonal) antibody was generated at Covance against NS5BCD21 protein as an antigen. NORE1A (rabbit polyclonal) has been described. (16) Antibodies against NORE1A (mouse monoclonal), HA (mouse monoclonal), GFP (mouse monoclonal), actin (rabbit polyclonal), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; mouse monoclonal) were purchased from Santa Cruz Biotechnology, Santa Cruz CA. Anti-BrU (5-bromouridine; rabbit polyclonal) was purchased from Thermo Fisher Scientific, Waltham MA. Antiubiquitin (rabbit polyclonal) was a kind gift from Dr. Melissa Rogers. Horseradish peroxidase-tagged antirabbit, antimouse antibodies and fluorescein isothiocyanate (FITC)-tagged antirabbit, cyanine 3 (Cy) 3-tagged antimouse antibodies were purchased from Jackson Immunoresearch, Bar Harbor, ME.
CELL TRANSFECTION, IMMUNOPRECIPITATION, AND IMMUNOBLOTTING
For immunoprecipitation (IP) analysis, or protein pull-down (glutathione S-transferase [GST]/GST-NS5B) studies, cells (transfected/control) in a 10-cm dish were washed twice with chilled phosphatebuffered saline (PBS; pH 7.4) and lysed with 400 lL of lysis buffer A (50 mM of Tris-Cl [pH 7.5], 120 mM of NaCl, and 1% Triton X-100) supplemented with 13 protease inhibitor cocktail (Roche Applied Science, Penzberg, DE), followed by centrifugation at 13,000 rpm for 10 minutes. Cleared lysates were incubated either with GST proteins or immunoprecipitated with antibodies overnight at 48C, and precipitates were collected by incubating with glutathione beads (SigmaAldrich) or protein G/A beads (Sigma-Aldrich), respectively, for 1 hour at 48C. pNTAP-tagged NS5BCD21 proteins with SQUAMOSA promoter binding protein-like motif were affinity purified by binding with streptavidin beads for 2 hours at 48C. Beads were washed three times with 0.1% lysis buffer A, and precipitates were then boiled 5 minutes in Laemmli sample buffer and stored at -208C. Samples were resolved on polyacrylamide gel and transferred onto nitrocellulose membranes (Millipore) for western blotting. Ras activivty in primary samples was determined using an Ras G-LISA kit from Cytoskeleton Inc. (Denver, CO).
SHORT HAIRPIN RNA KNOCKDOWN AND COLONY FORMATION ASSAY
MH14 cells were seeded in 10-cm dishes at 30%-40% confluence and, 16 hours postseeding, transfected with 500 ng of NORE1 short hairpin RNA (shRNA) or shRNA pRS vector in triplicate using Lipofectamine reagent. Two 10-cm dishes were mock transected. Plates were incubated for 24 hours at 378C. Twenty-four hours posttransfection, medium was replaced with complete medium containing G418 (300 lg/mL) and puromycin (1 lg/mL) in transfected plates. Untransfected plates were treated with either G418 alone and or with puromycin1G418.
COMPLEMENTARY DNA PREPARATION AND REAL-TIME PCR
Total RNA was prepared from cells using an RNAeasy mini kit (Qiagen, Rockville, MD) and quantified by nanodrop. Quality of RNA was verified by running on agarose gel. Equal amounts of RNA from each sample were subjected to first-strand complementary DNA (cDNA) synthesis by using a first-strand cDNA synthesis kit (Applied Biosystem, Foster City, CA) and gene-specific reverse primer for 5 0 NTR (nontranslated region) cDNA or random primers for NORE1A and NORE1B and actin cDNA preparation. Real-time PCR mixture was prepared by combining one tenth of cDNA prepared, 23 SYBR Green Mix (Applied Biosystems), and forward and reverse primers as per the manufacturer's instructions. Fluorescent signals were analyzed by ABI 7500 software (Applied Biosystems). Primer pairs used were as follows: forward 5 0 -CGG GAG AGC CAT AGT GG-3 0 and reverse; 5 0 -AGT ACC ACA AGG CCT TTC G-3 0 for 5 0 NTR amplification and forward; 5 0 -CGT GGG GCG CCC CAG GCA CCA-3 0 and reverse; 5 0 -TTG GCC TTC GGG TTC AGG GG-3 0 for actin, forward "CCG CGC TAT CTA CAG AGC" and reverse "GGG GGC TCC AGG TTC" for NORE1A, forward "GGC GGG CGC TGT GTC and reverse "GGC GGG CGC TGT GTC TCC" for NORE1B amplification. For human specimens, NORE1A expression was assessed by using a primer pair specific for exon 2a (5 0 -ATCCAGTTG-GACTGCAGTCA-3 0 ) and exon 4 (5 0 -GGGATTGTCCACAACCATG-3 0 ) to give an expected product size of 450 base pairs. In all RT-PCR reactions, expression of b-Actin was used as a positive control. All experiments were performed in triplicate and analyzed using ABI 7500 software (Applied Biosystems).
DUAL IMMUNOFLOURESCENCE ANALYSIS
NS5B stable and replicon cells were seeded on a cover glass, fixed (4% formaldehyde), blocked, and permeabilized, incubating with a mixture of anti-NS5B (mouse monoclonal) and anti-NORE1A (rabbit polyclonal) for 1 hour. Cells were washed with chilled 13 PBS and then subjected to antibody incubation with FITC-tagged goat antirabbit and Cy5-tagged Donkey antimouse secondary antibodies, respectively. A nucleus staining was performed with 1 lg/mL of 4 0 ,6-diamidino-2-phenylindole (DAPI) at room temperature.
PROTEINASE K DIGESTION AND 5
0 BrU LABELING OF NASCENT HCV RNA Localization of endogenous NORE1A and newly synthesized HCV RNA was performed as reported earlier for other host proteins in a replicon cell-based system. (17) 
PROTEASOME INHIBITORS AND CELLULAR UBIQUITINATION ASSAYS
Cells were seeded into six-well plates, grown to 50% confluence, and transfection was carried out using GFP-NORE1A plasmid. Twenty-four hours posttransfection, cells were either treated with dimethyl sulfoxide (DMSO) or 10 lM of MG132 or 1 lM of N-Acetyl-Leu-Leu-Nle-CHO (ALLN; Calbiochem, La Jolla CA) and further incubated for 16 hours at 378C. Cells were observed under a fluorescent microscope and pictures were taken using SPOT advanced software. Samples were harvested, immunoblotted, and analyzed using anti-GFP, antiubiquitin, anti-GAPDH, and anti-NS5B antibodies.
COIMMUNOPRECIPITATION OF HCV NS5B WITH UBIQUITNATED NORE1A
For detection of ubiquitinated NORE1A, replicon cells (MH14/C-5B) and 2.3 cells were transfected with GFP-NORE1A plasmid. Twenty-four hours posttransfection, cells were treated with either DMSO or MG132 (10 lM) and further incubated for 16 hours at 378C. Cells were lysed in buffer A (50 mM of Tris.Cl [pH 7.5], 120 mM of NaCl, and 0.75% Triton X-100) and immunoprecipated using anti-GFP antibodies and immunoblotted using anti-GFP, anti-NS5B, and antiubiquitin antibodies. For detection of endogenous ubiquitinated NORE1A, cells were treated with DMSO or MG132 and immunoprecipitated using anti-NORE1A antibodies and samples were immunoblotted using anti-NORE1A, anti-NS5B, and antiubiquitin antibodies. For determination of association of NS5B with ubiquitinated NORE1A, replicon cells, 2.3 cells, and control 293 cells were transfected with 2.0 lg of HA-ubiquitin expression vector or control plasmid. At 36 hours posttransfection, cells were treated with MG132 and incubated further at 378C for 16 hours. Cells were lysed in buffer A (50 mM of Tris.Cl [pH 7.5], 120 mM of NaCl, and 0.75% Triton X-100) and immunoprecipitated using anti-HA antibodies and immunoblotted using anti-NORE1A, anti-NS5B, and anti-HA antibodies.
PULSE CHASE ANALYSIS
HCV replicon, 2.3 cells, and 293 and Huh7 cells were seeded in a 6-cm dish at 50%-60% confluence. Twenty-four hours postseeding, cells were treated with 10 lCi of S35 in methionine free medium for 30 minutes at 378C. Medium was replaced with complete medium, and cells were further incubated at 378C. Cells were harvested at 0, 1, 2, and 3 hours posttreatment in buffer A (50 mM of Tris.Cl [pH 7.5], 120 mM of NaCl, and 0.75% Triton X-100). Lysates were immunoprecipitated using anti-NORE1A antibodies (rabbit polyclonal) and ran on sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE). Gel was dried and subjected to phosphor imaging for quantification. Intensity of bands was quantified using ImageQuant5.2 software.
CLINICAL SAMPLES DETAILS
Liver samples were kindly provided by Dr. Snorri Thorgeirsson (National Cancer Institute, Bethesda, MD) and the Liver Tissue Procurement and Distribution System (LTPDS), which was funded by National Institutes of Health (NIH) contract no. N01-DK-9-2310. Institutional review board approval was obtained at participating hospitals in the LTPDS (University of Minnesota, Minneapolis, MN and University of Pittsburgh, Pittsburgh, PA) and the NIH.
STATISTICAL ANALYSIS
Statistical analysis was by analysis of variance.
Results
HCV NS5B INTERACTS WITH NORE1A
Using a BacterioMatch two-hybrid system, we identified NORE1A as an NS5B-binding partner protein.
To validate this interaction in cells, we investigated NS5B-NORE1A complexes in C-5B cells containing the autonomously replicating HCV RNA. Endogenous NORE1A was detected in lysates of both Huh7.5 and C-5B cells, albeit to a relatively lower level in the latter (Fig. 1A, input) . When lysates were immunoprecipitated with anti-NS5B antibodies, a band corresponding to NORE1A was detected in C-5B lysates, but not in Huh7.5 lysates (Fig. 1A, top) . The specificity of this interaction was validated by observing the absence of NORE1A band when C-5B lysates were immunoprecipated with immunoglobulin G (IgG; Fig. 1A, bottom) . We then performed the reverse coimmunoprecipitation in C-5B cells. NS5B was easily detected in anti-NORE1A precipitates, but absent in reactions containing a nonspecific IgG (Fig.  1A, middle) .
We next analyzed this interaction in MH14 cells bearing the subgenomic HCV replicons. NORE1A was detected in MH14 lysates immunoprecipitated with anti-NS5B antibody, but not in Huh7.5 lysates immunoprecipitated with anti-NS5B or when M14 lysates were immunoprecipitated with nonspecific IgG antibodies (Fig. 1B, top and bottom) . Similarly, NS5B was detectable in MH14 lysates immunoprecipitated with anti-NORE1A antibodies (Fig. 1B, middle) . Because the MH14 subgenomic replicon does not contain the HCV structural proteins, the results suggest that the NS5B-NORE1A interaction occurs in the absence of HCV structural proteins. To further rule out the possibility of other HCV proteins mediating the NS5B-NORE1A interaction, we repeated our experiments in 2.3 cells, which stably express the NS5B protein (Fig. 1C) . Fluorescent microscopy was then used to confirm that NORE1A colocalizes with NS5B in both C-5B and 2.3 cells (Fig. 1D) .
EXPRESSION OF NS5B CORRELATES WITH DECREASED LEVELS OF NORE1A
NS5B has been reported to associate with the tumor suppressor, Rb, which leads to Rb degradation. (14, 22) We therefore hypothesized that NS5B may exert a similar effect on the NORE1A tumor suppressor. Therefore, we ectopically expressed GFP-NORE1A or the smaller isoform GFP-NORE1B expression plasmids in Huh7.5 and MH14 cells and visualized GFP expression 36 hours posttransfection ( Fig. 2A) . Expression of GFP-NORE1A, but not GFP-NORE1B, was dramatically reduced in MH14 cells relative to Huh7.5 cells.
To verify our results, we performed immunoblotting (IB) analysis of lysates obtained from MH14 and Huh7.5 cells expressing GFP, GFP-NORE1A, or GFP-NORE1B (Fig. 2B ). Consistent with our Fig.  2A observation, expression of GFP or NORE1B was unaffected in MH14 cells relative to Huh7.5. By contrast, the band corresponding to NORE1A was reduced by approximately 5.3-fold in lysates from MH14 cells when compared with Huh7.5 cells. We next examined the endogenous levels of NORE1A in C-5B, MH14, and 2.3 cells relative to their cognate control cells (Fig. 2C) . Similar to our data with ectopically expressed GFP-NORE1A, endogenous NORE1A levels were substantially reduced in both C-5B and MH14 cells when compared with Huh7.5 cells. Endogenous NORE1A levels were also sharply reduced in the NS5B stable cell line when compared to the parental 293 cells lacking NS5B (Fig. 2C) . To determine whether HCV-NS5B protein alone was sufficient to alter NORE1A expression, we transfected 293 cells with an GFP-NORE1A expression plasmid along with NS5B expression plasmid or cognate vector and analyzed their expression by IB analysis. Levels of GFP-NORE1A were reduced in the presence of NS5B when compared with cells transfected with empty vector (Fig. 2D) . Therefore, we conclude that NS5B down-regulates NORE1A expression in the absence of additional HCV proteins.
NS5B DECREASES NORE1A PROTEIN LEVELS THROUGH DEGRADATION MEDIATED BY THE HOST PROTEASOME
Several studies have reported on the epigenetic down-regulation of NORE1 in cancer. (23, 24) To determine whether NS5B might decrease expression of the NORE1A gene, we compared NORE1A mRNA levels in cells expressing either NS5B or the HCV replicon to their parent cell lines. NORE1A mRNA levels in 293 and 2.3 cells stably expressing NS5B were near equal (Fig. 3A) . Similarly, Huh7.5 cells and C-5B cells exhibited equal expression of NORE1A mRNA. By contrast, NORE1A mRNA was approximately 3-fold higher in MH14 cells versus Huh7.5 cells.
Given that the HCV replicon or NS5B expression alone does not decrease NORE1A mRNA, we next performed a pulse chase experiment to determine the stability of NORE1A protein in the presence of NS5B (2.3) or the MH14 HCV subgenomic replicon. Compared to control cells, levels of NORE1A protein decreased much faster in the presence of either NS5B or the MH14 replicon, suggesting that NS5B may alter the stability of the NORE1A protein (Fig. 3B) . . Relative expression of NORE1A and NORE1B in Huh7.5 and MH14 cells was analyzed on a SDS-PAGE. Anti-GFP, anti-NS5B, and GAPDH were used to probe immunoblottings. GAPDH was used as a loading control. (C) Lysates obtained from Huh7.5, C-5B, MH14, 293, or 2.3 cells were immunoblotted with anti-NORE1A, anti-NS5B, and anti-GAPDH to visualize relative levels of the endogneous proteins in each cellular lysate. GAPDH was used as a loading control. (D) Huh7.5 cells were transfected with GFP-NORE1A expression plasmid along with pNTAP vector or pNTAP-NS5BCD21 plasmid. Following 36 hours of incubation, cellular monolayers were lysed and IB analysis was performed using anti-GFP, anti-NS5B, and anti-GAPDH antibodies.
The half-life of NORE1A in 2.3 cells was approximately 30 minutes shorter than in 293 cells. The difference in the half-life was even more pronounced in MH14 versus Huh7 cells (2 vs. 3 hours, respectively). A previous study had reported that NORE1A is degraded by calpain-mediated proteolysis. (25) However, treatment with the calpain inhibitor, ALLN, failed to restore NORE1A levels in the Pulse chase analysis of NORE1A protein levels. Overnight cultured cells were subjected to 30 minutes of pulse in 35 S methioninesupplemented methionine free medium, cultured in complete medium for the indicated time, and immunoprecipitated with anti-NORE1A antibodies. Immunoprecipitated complexes were resolved on 10% SDS-PAGE and subjected to autoradiography. The intensity of bands corresponding to NORE1A was quantified using ImageQuant 5.2 software. (C) MH14 or 2.3 cells were transfected with GFP-NORE1A expression plasmid. Twenty-four hours posttransfection, cells were treated with either DMSO or MG132 for 16 hours. Fluorescent microscopy was utilized to visualize expression of GFP-NORE1A; quantification of fluorescence is shown top right of each panel in arbitrary units (ImageJ; NIH, Bethesda, MD). (D) C-5B, MH14, 2.3, Huh7, and 293 cells were transfected with GFP-NORE1A expression plasmid and treated with either DMSO (-) or MG132 (1) as described above. Cellular lysates were resolved on 10% SDS-PAGE and anti-GFP-, anti-NS5B-, and anti-GAPDH-specific antibodies were used for IB analysis to visualize bands corresponding to NORE1A, NS5B, and GAPDH, respectively.
FIG. 4. NS5B expression induces the polyubiquitination of NORE1A. (A,B) MH14
, C-5B, and 2.3 cells were transfected with GFP-NORE1A expression vector, and 24 hours posttransfection, cells were treated with either DMSO or 10 lM MG132 for an additional 16 hours. Lysates were immunoprecipitated with either anti-GFP (A) or anti-NORE1A antibodies. Immunoprecipitated complexes were resolved on SDS-PAGE, and IB analysis was performed using antiubiquitin, anti-NS5B, and anti-NORE1A antibodies. (C,D) Huh7.5, MH14, C-5B, 293, and 2.3 cells were transfected with HA-ubiquitin expression vector. Following 36 hours of incubation, cellular monolayers were lysed and immunoprecipitated with anti-HA antibodies. An aliquot of total lysate was resolved on SDS-PAGE (input) and immunoblotted with anti-NS5B antibodies as loading control. To determine whether the effect of NS5B was specific to the NORE1A Ras effector, we examined the ability of NS5B to suppress NORE1A protein expression in comparison to the Ras effector B-Raf. Transient transfections in HEK-293 cells showed that NS5B suppressed NORE1A expression almost completely, but had little or no effect on B-Raf. NS5B expression was detected with a polyclonal antibody, which gave rise to some nonspecific bands (NS) in the control panel.
presence of NS5B. NS5B down-regulation of Rb involves the host proteasome, and treatment with proteasome inhibitors reverses NS5B-induced degradation of Rb. (14) Therefore, we reasoned that NS5B might also induce NORE1A degradation in a process mediated by the host proteasome. To test our hypothesis, we visualized GFP-NORE1A protein levels in the presence or absence of the proteasome inhibitor, MG132. Treatment with MG132 enhanced expression of GFP-NORE1A, relative to DMSO-treated controls, in both MH14 and NS5B stable cell lines (Fig. 3C) . This was clearly evident from IB analysis of these cells subjected to MG132 treatment. Levels of GFP-tagged NORE1A increased dramatically upon treatment with MG132 in C-5B, MH14, and 2.3 cells relative to their cognate control cells (Fig. 3D) .
Given that ubiquitination is a key step in tagging proteins for degradation by the host proteasome, we tested NORE1A for ubiquitination in the presence and absence of NS5B. GFP-NORE1A was immunoprecipitated from lysates of MH14, C-5B, or the NS5B stable cell line that were treated with either DMSO or MG132. When the immunoprecipitated complexes were immunoblotted with antiubiquitin antibodies, a smear of higher-molecular-weight (HMW) products were detected and these HMW bands were enhanced in cells treated with MG132 (Fig. 4A) . A similar result was obtained when probing anti-NORE1A-immunoprecipitated complexes with antiubiquitin antibodies (Fig. 4B) . To investigate whether the HMW species were ubiquitinated NORE1A, we transfected Huh7.5, MH14, or C-5B cell lines with an HA-tagged ubiquitin-expressing plasmid. When the cellular lysates were immunoprecipitated with anti-HA antibody to pull down the HAtagged ubiquitin and subsequently immunoblotted with anti-NORE1A antibodies, a ladder of ubiquitinated NORE1A bands were visualized in C-5B and M14 cells, but not in Huh7.5 cells lacking the replicon, suggesting that NORE1A ubiquitination occurs in the presence of NS5B (Fig. 4C) . As further proof that NORE1A ubiquitination is mediated by NS5B and not additional HCV proteins, we performed a similar experiment in the NS5B stably expressing cell line. Similar to results obtained when using replicon cells, NORE1A ubiquitination was dependent on the presence of NS5B (Fig. 4D) . The effects of NS5B on NORE1A appeared to be specific given that we found that NS5B did not suppress the expression of a different Ras effector called B-Raf (Fig. 4E) .
NORE1A NEGATIVELY MODULATES HCV-RNA REPLICATION
HCV infection can activate the Ras pathway. (26) Furthermore, NORE1A is involved in a variety of antiproliferation and proapoptotic cellular responses to activated Ras. (27) So, it makes sense that HCV would need to suppress NORE1A function to avoid inducing death of its host cell. However, we wondered whether there might be a more significant biological reason for the interaction of NORE1A with NS5B. Perhaps NORE1A might have antiviral activity, and so HCV NS5B might induce NORE1A degradation as a means to enhance HCV replication. When we overexpressed GFP-tagged NORE1A in MH14 replicon-containing cells, NORE1A reduced the level of HCV-RNA replication by approximately 78% (Fig. 5A) .
To further confirm an antagonist role for NORE1A in modulating HCV replication, we used shRNA to knock down NORE1A in MH14 replicon-containing cells. Though levels of NORE1A protein are lower in this cell line than in Huh7.5 cells, a further reduction in expression of NORE1A was achieved upon treatment of NORE1A-specific shRNA (Fig. 5B, top panel) . Treatment of cells with the transfection reagent alone or scrambled shRNA had no detectable effect on HCV replication (Fig. 5B, lower panel) . However, treatment of replicon-containing cells with NORE1A-specific shRNA resulted in a greater than 2-fold enhancement of HCV-RNA replication (Fig. 5B, lower panel) . These data suggest that NORE1A antagonizes HCV replication, and that HCV may induce degradation of NORE1A in a process mediated by NS5B as a mechanism to promote viral replication.
NORE1A IS REDISTRIBUTED TO THE CYTOPLASM AND PERINUCLEAR REGION IN HCV REPLICONS AND NS5B STABLE CELLS
To investigate the cellular distribution of GFP-NORE1A in the presence of NS5B, we carried out live cell imaging of Huh7.5 and MH14 cells overexpressing GFP-NORE1A, GFP-NORE1B, or GFP alone (Fig. 6A ). NORE1A contains a nuclear localization signal and is reported to express predominantly in the nucleus, whereas expression of NORE1B is cytoplasmic. (28) Consistent with these reports, expression of GFP-NORE1A and GFP-NORE1B was nuclear and cytoplasmic in Huh7.5 cells. By contrast, GFP-NORE1A redistributed to the perinuclear region in MH14 replicons, whereas localization of GFP-NORE1B was similar to that observed in Huh7.5 cells.
We next carried out indirect immunofluorescence analysis to investigate whether GFP-NORE1A colocalized with NS5B in MH14 and 2.3 cells (Fig. 6B) . 293, 2.3, Huh7.5, and MH14 cells were transfected with GFP-NORE1A plasmid, and its expression and colocalization with NS5B was monitored 30 hours posttransfection. As expected, GFP-NORE1A exhibited a predominant nuclear localization in 293 and Huh7.5 cells. However, in both 2.3 and MH14 cells, GFP-NORE1A redistributed from the nucleus to the perinuclear region and colocalized with NS5B. This suggests that expression of NS5B alone is sufficient for redistribution of NORE1A, and that NS5B binding to NORE1A may prevent NORE1A from translocating to the nucleus.
The observation that NORE1A localizes with NS5B to the perinuclear region in the presence of the HCV replicon supports a model of NORE1A and NS5B localizing to active HCV replication complexes (RCs). To visualize nascent RNA synthesized in the RC in relationship to NS5B and NORE1A, we treated HCV C-5B/MH14 replicon cells with actinomycin D and BrU as described. (17) (18) (19) (20) We found that NORE1A localizes with HCV RNA, as indicated by a strong merged signal of NORE1A and BrU, suggesting that NORE1A is present in the HCV RC (Fig. 7A, white arrows) . Similar experiments were performed on Huh7 cells, and no perinuclear BrU staining was detectable (data not shown). HCV-RNA replication occurs in membranous web-like structures, (21, (29) (30) (31) (32) recently reported to be derived from the host secretory pathway. (33) To determine whether NORE1A may be present within these HCVgenerated intracellular membranes where RNA replication occurs, we treated cells with digitonin to disrupt the cellular membrane followed by treating cells with proteinase K (PK). (17, 21) This treatment results in the degradation of the majority of nonmembrane-bound proteins. Upon permeabilization with Triton X-100, fixing, and staining cells with anti-NORE1A and anti-BrU antibodies, we observed that a large portion of perinuclear NORE1A was resistant to PK treatment, suggesting that NORE1A is contained within intracellular membranes (Fig. 7B) . Upon Immunofluorescence analysis was performed with anti-NORE1A (green) and anti-BrU (red) antibodies. DAPI (blue) was used to visualize nuclei. Images were merged and regions of green (NORE1A) and red (HCV RNA) overlap are displayed in yellow highlighted by white arrowheads. (B) NORE1A associated with replicating HCV RNA is impermeable to PK. MH14 cells were treated with actinomycin D and BrU to label nascent HCV RNA. Before immunofluorescence analysis, replicon cells were treated with digitonin followed by PK. Cells were subsequently permeabilized with Triton X-100, fixed, and stained using either anti-NORE1A or anti-BrU antibodies. Images were merged and regions of NORE1A and BrU signal overlap are indicated in yellow.
FIG. 6.
NORE1A redistributes around perinuclear region and colocalizes with NS5B. Huh7.5 and MH14 cells were transfected with either EGFP, GFP-NORE1A, or GFP-NORE1B plasmids. Localization of EGFP or GFP-NORE1A was visualized using confocal microscopy. (B) Expression of NS5B shifts NORE1A localization to the perinuclear region. 293, 2.3, Huh7.5, and MH14 cells were transfected with GFP-NORE1A expression plasmid. Thirty-six hours posttransfection, cells fixed and subjected to immunofluorescence analysis using primary antibodies against NS5B (red) and DAPI (blue) to visualize nucleus. Images were merged, and overlapping regions of red NS5B and green GFP-NORE1A are indicated in yellow. Abbreviation: EGFP, enhanced green fluorescent protein.
merging NORE1A and anti-BrU, a strong colocalization, as indicated in yellow, was again observed in the perinuclear region of HCV replicon cells (Fig. 7B) . This observation indicates that a portion of NORE1A is present within HCV-modified membranes.
NORE1A PROTEIN LEVELS ARE FREQUENTLY DOWN-REGULATED IN HCV-INFECTED HUMAN LIVERS
If NS5B has a physiological role in suppressing NORE1A expression them, we might expect that HCV-infected humans would often exhibit suppressed NORE1A levels in the liver. We compared expression levels of NORE1A in primary, nontumorous (cirrhotic) liver samples associated with various etiologies to normal livers (Fig. 8 ). An example of the experimental data is shown in the upper panel and a summary in the lower panels. None of the hepatitis B virus (HBV)-infected livers or cirrhotic livers associated with ethanol consumption showed reduced protein levels of NORE1A protein when compared to normal liver. In contrast, decreased protein levels of NORE1A were detected in 10 of 18 (55%) HCV-infected livers (Fig.  8) . Curiously, all the HCV-infected samples that exhibited reduced NORE1A protein levels actually exhibited elevated NORE1A mRNA (left lower panel). Finally, given that NORE1A is a proapoptotic, prosenescent Ras oncoprotein effector, we examined levels of active Ras in the clinical samples. We found an almost perfect correlation between reduction of NORE1A expression and elevation of Ras activity (Fig. 8C) .
Discussion
HCV infection induces numerous changes in cellular signaling networks and predisposes to the development of HCC. (34) The mechanisms underlying the cancer-promoting effects of HCV remain poorly characterized. HCV infection causes general inflammation, which likely contributes to the progression to HCC. However, recent evidence suggests that certain HCV proteins can bind and inactivate key regulators of cellular growth, such as Rb, to facilitate virus replication. (14) Inactivation of such proteins has the additional effect of promoting cellular transformation. Here, we identify a new virus/host protein interaction system by showing that NS5B directly binds and promotes the degradation of the tumor suppressor, NORE1A.
NORE1A is a member of the RASSF family of tumor suppressors that is frequently subjected to epigenetic inactivation in human tumors. (35) NORE1A appears to serve as a major senescence effector of the Ras oncoprotein and couples Ras to the regulation of both p53 and Rb. (27) We have previously found that aberrant NORE1A promoter methylation is common in malignant HCC and correlates with loss of senescence markers. (15, 36) Therefore, NS5B-NORE1A interaction resulting in NORE1A protein degradation may be an additional factor that leads to the progression to HCC during chronic HCV infections.
To define the mechanism by which NS5B suppresses NORE1A, we examined mRNA expression and protein stability. We found no evidence that HCV suppresses NORE1A epigenetically or transcriptionally. Indeed, NORE1A mRNA actually increases in infected primary liver samples whereas protein levels are decreased. We observed NS5B induced ubiquitination of NORE1A and found that we could block the degradation of NORE1A by the use of proteasome inhibitors. Therefore, it appears that turnover of NORE1A is mediated by the host proteasome during HCV infection. We speculate that the increase in NORE1A transcription observed in infected livers is an antiviral response that is blocked by viral-mediated degradation of the protein.
NS5B-induced degradation of Rb by NS5B (22) was found to involve recruitment of E6AP to NS5B-Rb complexes. (14) Our preliminary data suggest that NS5B-NORE1A and E6AP complexes form in cells, though further investigation is required before we are able to definitively implicate E6AP as involved in NS5B-induced degradation of NORE1A (data not shown).
One of the most obvious questions arising from this study is what role NORE1A plays during HCV infection. We observed that overexpression of NORE1A antagonizes HCV-RNA replication. Conversely, further knockdown of NORE1A levels in repliconexpressing cells using shRNA resulted in greater than 2-fold increase in HCV-RNA replication. If NORE1A functions in an antiviral role, then it is not surprising that HCV has evolved a mechanism to counteract the effects of NORE1, specifically by binding NORE1A and inducing its degradation. How NORE1 might antagonize HCV replication will be the subject of future investigations. One plausible mechanism may lie in the role of NORE1 in Ras pathways. HCV infection activates the Ras pathway, and it is believed that constitutive activation of Ras enhances HCV replication. (26, 37) Furthermore, HCV-RNA replication was observed to be enhanced during the S phase, and cap-independent translation of the HCV polyprotein is more efficient in active replicating than in resting cells. (38, 39) Given that NORE1 promotes apoptosis and/or senescence in the presence of activated Ras, (16, (40) (41) (42) its presence may restrict the ability of host cells to support viral replication. In primary human liver samples, we observed an almost perfect correlation with suppression of NORE1A protein by HCV and up-regulation of Ras activity. Therefore, it is tempting to speculate that HCV NS5B binds and induces the degradation of NORE1A as a mechanism to shift Ras signaling to proliferation and away from growth inhibition/cell death responses, thus ensuring survival and replication of the HCV genome while simultaneously promoting malignancy.
Alternatively, we cannot discount the possibility that NORE1A expression may directly antagonize the polymerase activity of NS5B or negatively impact an additional HCV replication process. NS5B interacts with a variety of host and HCV proteins to form the replicase complex. Furthermore, oligomerization of NS5B is required for efficient polymerase activity. (43) (44) (45) An interesting possibility might be that the NORE1A protein disrupts HCV RCs by inhibiting NS5B oligomerization and/or reducing the efficiency of the NS5B polymerase activity. In support, we observed that NORE1A colocalizes with both NS5B and nascent HCV RNA in replicon cells. However, whether NORE1A is actively antagonizing the formation of RCs or whether the presence of NORE1A at the RC is merely a consequence of NS5B recruitment remains to be tested.
In conclusion, HCV NS5B induces the degradation of the tumor suppressor, NORE1A. Interestingly, we found that degradation of NORE1A occurred in some cirrhotic livers during chronic HCV infection, but not in cirrhotic livers as a result of HBV infection or ethanol consumption. Down-regulation of NORE1A occurs during the development of many forms of cancer. (35) Therefore, HCV-mediated down-regulation of NORE1A might be one of several preliminary steps in the progression to HCC during chronic HCV infection. Development of novel NS5B inhibitors that target NS5B-NORE1 interaction may represent a novel strategy to inhibit HCV replication and also prevent chronic HCV infections from progressing to HCC.
